Show simple item record

dc.contributor.authorCano Cano, Fátima 
dc.contributor.authorLara Barea, Almudena
dc.contributor.authorCruz Gómez, Álvaro Javier 
dc.contributor.authorMartín Loro, Francisco
dc.contributor.authorGómez Jaramillo, María Laura 
dc.contributor.authorGonzález Montelongo, María del Carmen 
dc.contributor.authorRoca Rodríguez, María del Mar
dc.contributor.authorBeltrán Camacho, Lucía 
dc.contributor.authorForero, Lucía
dc.contributor.authorGonzález Rosa, Javier Jesús 
dc.contributor.authorDurán Ruiz, María del Carmen 
dc.contributor.authorArroba Espinosa, Ana Isabel 
dc.contributor.authorAguilar Diosdado, Manuel 
dc.contributor.otherAnatomía y Embriología Humanaes_ES
dc.contributor.otherBiomedicina, Biotecnología y Salud Públicaes_ES
dc.contributor.otherMedicinaes_ES
dc.contributor.otherPsicologíaes_ES
dc.date.accessioned2025-05-26T06:55:06Z
dc.date.available2025-05-26T06:55:06Z
dc.date.issued2025-02
dc.identifier.issn1528-3658
dc.identifier.issn1076-1551
dc.identifier.urihttp://hdl.handle.net/10498/36356
dc.description.abstractBackground: Interest in the study of type 1 diabetes mellitus (T1DM) and multiple sclerosis (MS) has increased because of their significant negative impact on the patient quality of life and the profound implications for the health care system. Although the clinical symptoms of T1DM differ from those of MS, such as pancreatic β-cell failure in T1DM and demyelination in the central nervous system (CNS) in MS, both pathologies are considered as autoimmune-related diseases with shared pathogenic pathways, which include autophagy, inflammation and degeneration, among others. Considering the challenges in obtaining pancreatic β-cells and CNS tissue from patients with T1DM and MS, respectively, it is fundamental to explore alternative methods for evaluating disease status. Proteomic analysis of peripheral blood mononuclear cells (PBMCs) is an ideal approach for identifying novel and potential biomarkers for both autoimmune diseases. Methods: We conducted a proteomic analysis of PBMCs from patients with T1DM and relapsing remitting Multiple Sclerosis (herein forth MS) patients (n = 9 per condition), using a label-free quantitative proteomics approach. The patients were diagnosed following the American Diabetes Association (ADA) criteria for T1DM and McDonald criteria for MS respectively, and were aged over 18 years and more than 2 years from the onset respectively. Results: A total of 2476 proteins were differentially expressed in PBMCs from patients with T1DM and MS patients compared with those form healthy controls (H). Predictive analysis highlighted 15 common proteins, up- or downregulated in PBMCs from patients with T1DM and MS patients vs. healthy controls, involved in the immune system activity (BTF3, TTR, CD59, CSTB), diseases of the neuronal system (TTR), signal transduction (STMN1, LAMTOR5), metabolism of nucleotides (RPS21), proteins (TTR, ENAM, CD59, RPS21, SRP9) and RNA (SRSF10, RPS21). In addition, this study revealed both shared and distinct molecular patterns between the two conditions. Conclusions: Compared with H, patients with T1DM and MS presented a specific expression pattern of common proteins has been identified. This pattern underscores the shared mechanisms involved in their immune responses and neurological complications, alongside dysregulation of the autophagy pathway. Notably, CSTB has emerged as a differential biomarker, distinguishing between these two autoimmune diseases.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherSpringer Naturees_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceMolecular Medicine, Vol. 31, Núm. 1, 2025es_ES
dc.titleExploring proteomic immunoprofiles: common neurological and immunological pathways in multiple sclerosis and type 1 diabetes mellituses_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.1186/S10020-025-01084-X
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PID2023-147093OB-I00/ES/CAMBIOS LONGITUDINALES EN BIOMARCADORES SERICOS Y DE NEUROIMAGEN SUBYACENTES AL DECLIVE COGNITIVO EN PACIENTES CON ESCLEROSIS MULTIPLE \u0093DE NOVO\u0094 Y DE DIAGNOSTICO RECIENTE./es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023/PI22%2F01718/ES/La inmunomodulación es una nueva diana terapéutica de la diabetes mellitus tipo 1. Uso de sp2-iminoglicolípidos como tratamientos inspirados en biomoléculas.es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/Junta de Andalucía//PI0036-2020es_ES
dc.type.hasVersionVoRes_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This work is under a Creative Commons License Atribución 4.0 Internacional